Literature DB >> 11973173

Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP).

Jeroen de Jonge1, Theo H N Groenland, Herold J Metselaar, Jan N M IJzermans, Huub H D M van Vliet, Loes Visser, Hugo W Tilanus.   

Abstract

UNLABELLED: After the introduction of solvent/detergent-treated plasma (ESDEP) in our hospital, an increased incidence of hyperfibrinolysis was observed (75% vs 29%; P = 0.005) compared with the use of fresh frozen plasma for liver transplantation. To clarify this increased incidence, intraoperative plasma samples of patients treated with fresh frozen plasma or ESDEP were analyzed in a retrospective observational study. During the anhepatic phase, plasma levels of D-dimer (6.58 vs 1.53 microg/mL; P = 0.02) and fibrinogen degradation products (60 vs 23 mg/L; P = 0.018) were significantly higher in patients treated with ESDEP. After reperfusion, differences increased to 23.5 vs 4.7 microg/mL (D-dimer, P = 0.002) and 161 vs 57 mg/L (fibrinogen degradation products, P = 0.001). The amount of plasma received per packed red blood cell concentrate, clotting tests, and levels of individual clotting factors did not show significant differences between the groups. alpha(2)-Antiplasmin levels, however, were significantly lower in patients receiving ESDEP during the anhepatic phase (0.37 vs 0.65 IU/mL; P < 0.001) and after reperfusion (0.27 vs 0.58 IU/mL; P = 0.001). Analysis of alpha(2)-antiplasmin levels in ESDEP alone showed a reduction to 0.28 IU/mL (normal >0.95 IU/mL) because of the solvent/detergent process. Therapeutic consequences for the use of ESDEP in orthotopic liver transplantation are discussed in view of an increased incidence of hyperfibrinolysis caused by reduced levels of alpha(2)-antiplasmin in the solvent/detergent-treated plasma. IMPLICATIONS: The use of solvent/detergent virus-inactivated plasma is of increasing importance in the prevention of human immunodeficiency virus and hepatitis C virus transmission. Since the use of this plasma during orthotopic liver transplantation has increased, the incidence of hyperfibrinolysis was observed. Clotting analysis of the patients revealed small alpha(2)-antiplasmin concentrations because of the solvent/detergent process.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11973173     DOI: 10.1097/00000539-200205000-00012

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  11 in total

1.  Are inactivation procedures for blood products good or bad?

Authors:  Gregor Caspari
Journal:  BMJ       Date:  2002-11-09

Review 2.  [Fresh plasma and concentrates of clotting factors for therapy of perioperative coagulopathy: what is known?].

Authors:  B Heindl; M Spannagl
Journal:  Anaesthesist       Date:  2006-09       Impact factor: 1.041

Review 3.  Recommendations for the transfusion of plasma and platelets.

Authors:  Giancarlo Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2009-04       Impact factor: 3.443

4.  Plasma, guidelines, and evidence-based medicine.

Authors:  Roberto Reverberi
Journal:  Blood Transfus       Date:  2008-01       Impact factor: 3.443

5.  Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma.

Authors:  Giancarlo Maria Liumbruno; Maria Laura Sodini; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2008-01       Impact factor: 3.443

Review 6.  Is solvent/detergent plasma better than standard fresh-frozen plasma? A systematic review and an expert consensus document.

Authors:  Marco Marietta; Massimo Franchini; M Lucia Bindi; Francesco Picardi; Matteo Ruggeri; Giustina De Silvestro
Journal:  Blood Transfus       Date:  2016-02-17       Impact factor: 3.443

Review 7.  Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.

Authors:  Americo Cicchetti; Alexandra Berrino; Marina Casini; Paola Codella; Giuseppina Facco; Alessandra Fiore; Giuseppe Marano; Marco Marchetti; Emanuela Midolo; Roberta Minacori; Pietro Refolo; Federica Romano; Matteo Ruggeri; Dario Sacchini; Antonio G Spagnolo; Irene Urbina; Stefania Vaglio; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2016-07       Impact factor: 3.443

8.  Low incidence of hyperfibrinolysis and thromboembolism in 195 primary liver transplantations transfused with solvent/detergent-treated plasma.

Authors:  Håkon Haugaa; Eli Taraldsrud; Hans Christian Nyrerød; Tor Inge Tønnessen; Aksel Foss; Bjarte G Solheim
Journal:  Clin Med Res       Date:  2014-01-10

9.  [Coagulation therapy in multiple trauma without point-of-care testing].

Authors:  H Lier; J Hinkelbein
Journal:  Unfallchirurg       Date:  2014-02       Impact factor: 1.000

10.  Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026).

Authors:  Chintamani Atreya; Simone Glynn; Michael Busch; Steve Kleinman; Edward Snyder; Sara Rutter; James AuBuchon; Willy Flegel; David Reeve; Dana Devine; Claudia Cohn; Brian Custer; Raymond Goodrich; Richard J Benjamin; Anna Razatos; Jose Cancelas; Stephen Wagner; Michelle Maclean; Monique Gelderman; Andrew Cap; Paul Ness
Journal:  Transfusion       Date:  2019-05-29       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.